

Technology Appraisal Committee Meeting Committee C Manchester

Minutes: Confirmed

Date and Time: Tuesday 5 February 2019

Present:	1. Professor Stephen O'Brien (Chair) 2. Alex Cale 3. Andrew Renahan 4. David Chandler 5. Derek Ward 6. Gail Coster 7. John Hampson 8. Natalie Hallas 9. Nicholas Latimer 10. Nigel Langford 11. Paul Tappenden 12. Peter Selby 13. Richard Nicholas 14. Rob Forsyth 15. Stella O'Brien 16. Ugochinyere Nwulu	Present for all notes Present for notes 9 to 14 Present for all notes Present for all notes
-----------------	---	--

In attendance:

Helen Knight	Programme Director, National Institute for Health and Care Excellence	Present for all notes
Jasdeep Hayre	Associate Director, National Institute for Health and Care Excellence	Present for notes 9 to 14
Janet Robertson	Associate Director, National Institute for Health and Care Excellence	Present for notes 1 to 8
Stephanie Callaghan	Project Manager, National Institute for Health and Care Excellence	Present for all notes
James Maskrey	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Pratit Shah	Project Manager, National Institute for Health and Care Excellence	Present for all notes
Lyudmila Marinova	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 1 to 8

Alexander Filby	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 1 to 8
Lorna Dunning	Technical Analyst, National Institute for Health and Care Excellence	Present for notes 9 to 14
Jamie Elvidge	Technical Adviser, National Institute for Health and Care Excellence	Present for notes 9 to 14

Non-public attendees:

Paul Tappenden	ERG Representative	Present for notes 1 to 5
Emma Simpson	ERG Representative	Present for notes 1 to 5
Angela Stainthorpe	ERG Representative	Present for notes 9 to 11
Rachel Houten	ERG Representative	Present for notes 9 to 11
Peter Clark	CDF Clinical Lead	Present for all notes
Adele Fielding	Clinical Expert	Present for notes 1 to 5
Nick Morley	Clinical Expert	Present for notes 1 to 5
Zack Pemberton-Whiteley	Patient Expert	Present for notes 1 to 5
Gavin Stewart	Company Representative	Present for notes 1 to 5
Manoj Prahladan	Company Representative	Present for notes 1 to 5
Holly Cranmer	Company Representative	Present for notes 9 to 11
Tanja Podkonjak	Company Representative	Present for notes 9 to 11
Trudie Willingham	Observer	Present for all notes
Daisy Ives	Observer	Present for all notes
Leslie Hayes	Observer	Present for all notes
Izabela Syrek	Observer	Present for all notes
Verena Wolfram	Observer	Present for all notes
Tom Strong	Observer	Present for all notes
Eric Power	Observer	Present for all notes
Nicole Elliott	Observer	Present for all notes

Notes

Any other Business

1. None

Minutes from the last meeting

2. The committee approved the minutes of the committee meeting held on Tuesday 27 November 2018.

Appraisal of Blinatumomab for treating minimal residual B-precursor acute lymphoblastic leukaemia in remission [ID1036]

Part 1 – Open session

3. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Amgen UK.
4. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests
 - 4.1. Adele Fielding declared a non-personal specific financial interest as she took part in public advisory boards, a clinical trial funded by Amgen and she received speaker fees for conferences by Amgen.
 - 4.1.1. It was agreed that this declaration would not prevent Adele Fielding from participating in this section of the meeting.
 - 4.2. Nick Morley declared a non-personal specific non-financial interest as he took part in three clinical trials for leukaemia which were funded by Amgen.
 - 4.2.1. It was agreed that this declaration would not prevent Nick Morley from participating in this section of the meeting.
 - 4.3. Zack Pemberton-Whiteley declared a non-personal specific financial interest as his organisation, Leukaemia Care received funding from a comparator company and Amgen.
 - 4.3.1. It was agreed that this declaration would not prevent Zack Pemberton-Whiteley from participating in this section of the meeting.
 - 4.4. Paul Tappenden declared a personal specific non-financial interest as he is representing the ERG, School of Health & Related Research at the University of Sheffield for this topic.

4.5. It was agreed that this declaration would prevent Paul Tappenden from participating as a member of the committee in this section of the meeting.

4.6. No further conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)

5. The committee discussed confidential information submitted as part of this appraisal.

Part 2b – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

6. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.

7. The committee decision was based on consensus.

8. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Appraisal of Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma [ID1190]

Part 1 – Open session

9. The Chair welcomed the invited clinical and patient experts, Evidence Review Group (ERG)/Assessment Group (AG) representatives and representatives from Takeda Ltd.

10. The Chair asked all committee members, experts, ERG/AG representatives and NICE staff present to declare any relevant interests

10.1. No conflicts of interest were declared for this appraisal.

Part 2 – Closed session (company representatives, clinical and patient experts and members of the public were asked to leave the meeting)

11. The committee discussed confidential information submitted as part of this appraisal.

Part 2b – Closed session (company representatives, clinical and patient experts, ERG/AG representatives and members of the public were asked to leave the meeting)

12. Agreement on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) was discussed by the committee.

13. A vote was taken. The options were:

Option 1: For recommendation

Option 2: Request further data

The committee voted for Option 1.

Details of the result of this discussion will be included in the confirmed version of these minutes, which will be published during the week commencing 21 March 2019 after the publication of all decisions taken at this Committee meeting.

14. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD) in line with their decisions.

Date, time and venue of the next meeting:

Wednesday 6 March 2019 from 10am to 5pm at National Institute of Health & Care Excellence, Level 1A, City Tower, Piccadilly Plaza, Manchester, M1 4BT.